Novo Nordisk announced a strategic AI partnership with OpenAI covering drug discovery, clinical development, manufacturing, supply chain, and commercial operations. OpenAI models will be applied to analyze complex biological datasets, identify drug candidates, and reduce clinical development timelines. Pilot programs are launching across R&D, manufacturing, and commercial operations, with full integration targeted for late 2026. OpenAI will also support AI upskilling across Novo's global workforce. The partnership includes data governance and human oversight requirements. Novo cited competitive pressure from Eli Lilly in the obesity and diabetes market as strategic context.